Category Archives: Inside BIO Industry Analysis

Forecasted Sales Growth of Top Therapeutic Areas: Anti-Coagulants to Outpace

Although oncology has the largest market share in the therapeutics business, anti-coagulant products are expected to grow at the fastest rate among the top 15 therapeutic categories, according to a new report from EvaluatePharma. Below is a chart of future growth rates based on data from their “World Preview 2013, Outlook to 2018” report. Their data is based on analyst estimates for marketed and pipeline drugs globally. Following the anti-coagulants are oncology and diabetes drugs Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post

R&D – Slow Growth Continues

According to a new report from EvaluatePharma, global pharmaceutical R&D had negative growth in 2012 and is expected to only grow at a snail’s pace over the next five years. As seen in the chart below, industry spending on R&D actually started contracting in 2009 and has been on a new, slower trajectory ever since. To create the chart above, we combined numbers in the new report with previous EvaluatePharma reports for 2000-2004. From the start of the 2000s Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post

Industry Growth Factor: Biologics

Graph

Last week, EvaluatePharma released their updated sales and R&D outlook for the drug industry in their report “World Preview 2013, Outlook to 2018”. Among the 37 pages of data, one central take home message was that growth will return to the sector after a small dip in 2012. Behind this predicted comeback in sales growth is the rise of biologics products that continue to gain a larger percentage of total revenue. Consider the data below taken from Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Only 12% of Public Biotechs are Profitable

Of the 286 biotech companies trading on public exchanges today, 241 focus on drug development, a slight drop in numbers from last year.* Of these 241 in the biopharmaceutical space, only 28 (12%) had both a product on the market and positive net income for FY 2012. This is about the same as the 13% reported last year, but different companies populate the list.  Unlike our last report (May 2012), when acquisitions of profitable companies Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post

Breakthrough Designations Reach 13

One of the outcomes of the 2012 Food and Drug Administration Safety and Innovation Act (FDASIA) was the creation of the “Breakthrough Therapy” designation.  The new law allows FDA to grant a Breakthrough Therapy designation to drugs showing early clinical promise for serious or life-threatening conditions, thereby expediting both the development and the review of these drugs. As of today, 13 designations have been granted according to a search of the BioMedTracker database (see table Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post